Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares of the company’s stock, valued at $2,755,405.56. This represents a 1.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Chimerix Price Performance
Shares of CMRX opened at $4.38 on Monday. Chimerix, Inc. has a one year low of $0.75 and a one year high of $4.65. The firm has a market capitalization of $393.94 million, a P/E ratio of -4.66 and a beta of 0.35. The business has a fifty day moving average of $3.53 and a 200 day moving average of $1.83.
Institutional Trading of Chimerix
Large investors have recently modified their holdings of the company. Stoneridge Investment Partners LLC grew its holdings in Chimerix by 22.5% during the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 8,134 shares during the period. Bender Robert & Associates bought a new stake in Chimerix during the fourth quarter valued at about $37,000. Susquehanna Fundamental Investments LLC bought a new stake in Chimerix during the fourth quarter valued at about $59,000. Jane Street Group LLC bought a new stake in Chimerix during the fourth quarter valued at about $62,000. Finally, Diadema Partners LP bought a new stake in Chimerix during the fourth quarter valued at about $101,000. Institutional investors own 45.42% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Analysis on CMRX
About Chimerix
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Recommended Stories
- Five stocks we like better than Chimerix
- About the Markup Calculator
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- NYSE Stocks Give Investors a Variety of Quality Options
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- What is Forex and How Does it Work?
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.